New modified antibiotic may prove effective against >200 resistant pathogens
To create a novel molecule that may be effective against resistant Gram-negative bacteria, researchers at University of Illinois have modified an already existing antibiotic with highly promising results. Fabimycin, as the new molecules is called, showed remarkable results in combating more than 200 resistant Gram-negative bacteria while at the same time it had no effect on beneficial bacteria in the gut microbiota. Also, fabimycin showed efficacy against Gram-negatives in mouse infection models of a challenging urinary tract infection and of acute pneumonia.
The team of Dr. Paul J. Hergenrother, professor of chemistry at University of Illinois, sought to create a new antibiotic that would successfully accumulate inside Gram-negative bacteria. The researchers chose to target the FabI enzyme, which is responsible for catalyzing the rate-determining step in bacterial fatty acid biosynthesis. Before this study, the use of the FabI enzyme as an antibiotic target had only been leveraged in Gram-positive infections.
Their findings suggest that fabimycin could eventually be used to treat Gram-negative infections in humans.
Read the study results here: https://pubs.acs.org/doi/10.1021/acscentsci.2c00598